Canakinumab in pediatric rheumatic diseases.

about

The burgeoning field of innate immune-mediated disease and autoinflammation.

P2860

Q38967233-F4AC1248-F91D-46D2-BB68-5376E211DC4F

P2860

Canakinumab in pediatric rheumatic diseases.

Item

http://www.wikidata.org/entity/Q38085662

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Canakinumab in pediatric rheumatic diseases.

@en

type

Item

label

Canakinumab in pediatric rheumatic diseases.

@en

prefLabel

Canakinumab in pediatric rheumatic diseases.

@en

P1476

Canakinumab in pediatric rheumatic diseases.

@en

P2093

Nico M Wulffraat

http://www.w3.org/2001/XMLSchema#string

Patricia Woo

http://www.w3.org/2001/XMLSchema#string

P2860

Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes

De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases

Identification of a novel susceptibility locus for juvenile idiopathic arthritis by genome-wide association analysis.

Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.

An international registry on autoinflammatory diseases: the Eurofever experience.

Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition.

Interleukin-1β and interleukin-6 in arthritis animal models: roles in the early phase of transition from acute to chronic inflammation and relevance for human rheumatoid arthritis

A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.

A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)

The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis.

P304

615-622

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14712598.2013.778239

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23451862

http://www.w3.org/2001/XMLSchema#string

Canakinumab in pediatric rheumatic diseases.

about

P2860

P2860

Canakinumab in pediatric rheumatic diseases.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698